Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Expands bioprocessing footprint across Asia
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
HYMPAVZI’s safety profile was generally favorable
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
